Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

Here you will find a summary of Ironwood Pharmaceuticals, Inc.'s latest financial information.

Latest Annual Report/10-K

Form	Filing date	View
10-K	Feb 21, 2013	View HTML 0001047469-13-001388.pdf 0001047469-13-001388.rtf 0001047469-13-001388.xls EX-101.INS - EX-101.INS

Latest Proxy Statement

Form	Filing date	View
DEF 14A	Apr 18, 2012	View HTML 0001047469-12-004416.pdf 0001047469-12-004416.rtf 0001047469-12-004416.xls
DEF 14A	Apr 18, 2014	View HTML 0001047469-14-003952.pdf 0001047469-14-003952.rtf 0001047469-14-003952.xls
DEF 14A	Apr 18, 2017	View HTML 0001047469-17-002692.pdf 0001047469-17-002692.rtf 0001047469-17-002692.xls

Ironwood Pharmaceuticals
301 Binney Street
Cambridge, MA 02142

tel 617.621.7722
fax 617.494.0480

ABOUT US

Pharmaceutical
Advisory Committee

Transparency

Patient Assistance

Our MEDICINES

Overview

Discovery of Linaclotide

R&D

COLLABORATE

Accessing Additional Products

Globalization

Investors

NEWS

Join US

LINZESS® is a registered trademark of Ironwood Pharmaceuticals, Inc., ZURAMPIC®, DUZALLO® are registered trademarks of AstraZeneca AB Corporation or its affiliates and are used herein under license.

Market Capitalization (Mil)	$2,799.72
Shares Outstanding (Mil)	$153.16
Shares Outstanding, Average (FY) (Mil)	$148.99
Float (Mil)	$138.52

Financial Information

Latest Earnings Release and 10-Q

Latest Annual Report/10-K

Latest Proxy Statement

Share Related